IgA nephropathy
Conditions
Interventions
statin and losartan group: simvastatin 5mg and Losartan 50mg/day more than 3 months
statin group: simvastatin 5mg/day more than 3 months
Sponsors
Fukuoka University Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Men and women over the age of 20 2.Patients with dislipidemia(LDL cholesterol: 120 mg/dL or higher) 3.Patients who need a therapy of hypertention (JSH2009) 4.Patients not taking an ACE inhibitor or ARB within the last 3 months 5.Patients who have provided written consent
Exclusion criteria
Exclusion criteria: 1.Patients with type 1 diabetes mellitus 2.Patients with cardiovascular disease and with the following conditions Patients who have undergone coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the last 3 months, patients with unstable angina, patients with a history of myocardial infarction, patients with a history of a transient ischemic attack (TIA) within the last 6 months, patients that are NYHA functional class III or IV or with heart failure, and patients with a history of cerebral infarction within the last 3 months 3. serum Cr>2.5mg/dL or eGFR<30mL/min 4.Patients with severe liver dysfunction 5.Patients with secondary hypertension caused by factors other than diabetes mellitus 6.HbA1c > 9% 7.Patients with pregnancy or nursing 8.Other patients deemed ineligible by an investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effectiveness of reducing proteinuria in spot urine samples will be compared in a control group receiving statin therapy alone for 2 years and a treatment group given statin therapy and losartan. | — |
Countries
Japan
Contacts
Public ContactSatoru Ogahara
Fukuoka University Faculty of Medicine Division of Nephrology and Rheumatology, Department of Internal Medicine
Outcome results
None listed